FDA Can Expand Access To Experimental Drugs, Without Compromising Trials
Executive Summary
FDA would be able to maintain the integrity of rigorous clinical trials and permit increased access to experimental drugs through the use of better science, according to former FDA Deputy Commissioner for Medical & Scientific Affairs Scott Gottlieb